Hypovitaminosis C Prevalence and Risk Factors in an Acute Geriatric Unit
NCT ID: NCT05668663
Last Updated: 2025-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
434 participants
INTERVENTIONAL
2023-01-09
2024-05-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The term 'hypovitaminosis C' refers to a plasmatic Vitamin C concentration \< 28 µmol/L. It encompasses two distinct situations, according to the severity of the deprivation:
* A deeply lowered plasmatic concentration (\< 11 µmol/L) is defined as 'Vitamin C deficiency'. The resulting condition is scurvy and its well-known haemorrhagic complications, very likely to be fatal.
* A less low plasmatic concentration (11-27 µmol/L) is defined as 'Vitamin C depletion'. Symptoms are polymorphic and less suggestive, especially for elderly patients. Many studies suggest a chronic Vitamin C depletion may favour the occurrence of various conditions such as cognitive impairment, psychiatric disorders, cardio-vascular diseases, or certain cancers, thereby highlighting the involvement of Vitamin C in many biological processes.
The epidemiology and risk factors of hypovitaminosis C in ageing populations are poorly documented. The few studies dealing with this question are mostly retrospective, including a low number of patients, and relying on an imperfect methodology. Despite these limitations, data suggest hypovitaminosis C could concern up to 50% of the hospitalized geriatric population.
Despite this probably high prevalence, hypovitaminosis C is barely diagnosed and thus rarely supplemented. This is particularly true for the elderlies who are at risk high of being Vitamin C depleted.
Moreover, several risk factors have been described to be associated with Vitamin C depletion or deficiency, sometimes both. But only a few of them have been validated for the geriatric population.
Thus, there is a real need for a better understanding of hypovitaminosis C epidemiology and risk factors in the geriatric population, in order to diagnose earlier, more frequently, and more precisely these cases. It is important to note that an easy and safe supplementation exists (1 g of Vitamin C for 2 weeks).
A better understanding of risk factors is also a key element to apply corrective measures on modifiable risk factors in order to prevent the recurrence of hypovitaminosis C.
In the present research protocol, the investigators hypothesized hypovitaminosis C could concern half of the hospitalized geriatric patients in acute care units.
The primary objective of this study is to evaluate the prevalence of hypovitaminosis C in a geriatric acute care unit, by using a prospective design and including a statistically sufficient number of patients.
The secondary objectives are :
* To determine in this population the prevalence of Vitamin C deficiency,
* To determine in this population the prevalence of Vitamin C depletion,
* To assess the statistical associations between hypovitaminosis C, deficiency, and depletion with already known or pertinent risk factors.
* To follow adverse events with vitamin C supplementation in deficient patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Prevalence and Risk Factors of Hypovitaminosis C in Long Term Care Unit
NCT03807791
"Vitamin C Deficiency in Hospitalized Adults: Systematic Screening Vs. Traditional Judgment - a Before-and-After Observational Study"
NCT06876545
Vitamin C 4 Care Homes
NCT05122481
Hypovitaminosis D Prediction Score
NCT02822651
Urinary Vitamin C Loss in Diabetic Subjects
NCT00071526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly patients
Only one group of patients will be constituted. It will be composed of 453 patients aged more than 75 years old and hospitalized in a geriatric acute care unit.
If the patient consent to participate in the study, a 4-mL blood sample will be collected concomitantly with a general laboratory evaluation that will be performed when the patient enters the unit.
No other sample will be taken., and tThe participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effectswith this blood sample collection.
No further visit is organised.
Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample
If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.
The blood sample will be collected up to 3 days after admission
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasmatic Vitamin C concentrations (known as ascorbemia) on a single blood sample
If the patient consents to participate in the study, a 4-mL blood sample will be collected and performed when the patient enters the unit. No other sample will be taken, and the participation of the patient to the study will end after the result of the test or after the end of the vitamin C supplementation. A telephone call is organized to follow up on any adverse effects.
The blood sample will be collected up to 3 days after admission
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged more than 75 years-old.
* Patient able to consent having signed a consent or patient unable to give consent, informed and not opposed to the study to the study and for whom a trustworthy person, or failing that family, or failing that, a close relative, has signed an informed informed consent
* Patient affiliated to a social security system
Exclusion Criteria
* Patients at the end of their life. No biological sample will be collected
* Patients under a "sauvegarde de justice" procedurePatients under legal protection (guardianship, curatorship, "sauvegarde de justice" procedure),
* Patient unable to consent without a trusted person (or family, or close friends) or without a trusted person (or family, or close friend) available within 2 days after the patient's admission.
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Médecine Gériatrique of the Hôpital Edouard Herriot (Pavillon K)
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Quillon A, Guittard L, Goldet K, Etienne M, Blond E, Nourredine M, Martin-Gaujard G, Doh S. A cross-sectional study to evaluate hypovitaminosis C prevalence and risk factors in an acute geriatric unit in Lyon, France: the HYPO-VIT-C protocol. BMJ Open. 2023 Aug 23;13(8):e075924. doi: 10.1136/bmjopen-2023-075924.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A02234-39
Identifier Type: OTHER
Identifier Source: secondary_id
69HCL22_0883
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.